Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | TNKS | O95271 | 1/20 | 0.57 |
| ▸ | HTR3A | P46098 | 7/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3462908 | 0.87 | RAB9A (0.77) | RAB9ATNKSALDH1A1LMNA | |
| SCHEMBL23940238 | 0.84 | HTR3A (0.47) | TNKSHTR3ACNR1CNR2 | |
| SCHEMBL10388774 | 0.79 | HTR3A (0.67) | HTR3AALDH1A1 | |
| Hydrochloric Acid SCHEMBL10389213 | 0.78 | HTR3A (0.66) | HTR3A | |
| SCHEMBL27249980 | 0.76 | HTR3A (0.53) | RAB9AHTR3ANR4A2CNR1CNR2 | |
| SCHEMBL14183897 | 0.76 | RAB9A (0.49) | RAB9ATNKSHTR3AKMT2ABCHE | |
| SCHEMBL19902713 | 0.75 | TNKS (0.50) | RAB9ATNKSHTR3ANR4A2MITF | |
| SCHEMBL1093252 | 0.74 | BRD4 (0.69) | NR4A2MITFALDH1A1LMNAMAPT | |
| SCHEMBL23940225 | 0.74 | HDAC6 (0.56) | NR4A2MITFALDH1A1LMNAMAPT | |
| SCHEMBL13162693 | 0.74 | NPC1 (0.72) | RAB9AALDH1A1KMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323966-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-10-21 | — | — | US | disclosed |
| WO-2018093968-A1 | IMIDAZOPYRIDAZINE MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323966-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | TYK2, JAK3, JAK1 | RAB9A 3539/4885TNKS 348/4885HTR3A 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.